A randomized phase III study in previously untreated patients with biological highrisk

CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab

EudraCT nr.: 2005-000309-75 



 

Pełna wersja do pobrania w pliku PDF:
HO68 AM2 listofchanges 031008